Coronary heart disease (CHD) remains the leading cause of death in the United States, yet the tools doctors rely on for early detection are proving less reliable than many assume. Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) reports that approximately 50% of individuals with CHD do not present with traditional risk factors, and conventional risk calculators have an average sensitivity of only 39%. This means many who appear healthy may still develop CHD and suffer preventable cardiac events such as heart attacks.
For decades, cardiovascular risk assessment has centered on a checklist: cholesterol levels, blood pressure, smoking history, diabetes status, family history, and weight. While these factors are useful, they were never designed to capture the full biological picture of how heart disease develops. Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics, fields that examine how genes are expressed and regulated at the molecular level. By analyzing molecular markers, these tests aim to identify CHD risk with greater precision, potentially filling a critical gap in current screening methods.
The implications of this announcement are significant. If molecular testing can improve detection rates, it could lead to earlier interventions and reduce the number of preventable cardiac events. The company's approach may shift the paradigm from population-based risk scoring to personalized molecular assessment. For investors and healthcare providers, the news highlights the potential for advanced diagnostics to address a blind spot in cardiovascular medicine. More details are available in the company's newsroom at https://ibn.fm/CDIO.
